Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Dollar General Corp. (DG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Dollar General Corp. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Dollar General Corp. trades at $119.42 (market cap $26.23B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Dollar General Corp. pays a 1.98% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DG | |
|---|---|---|
Market Cap | $39.89B | $26.23B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $156.26 |
52-Week Low | $278.09 | $95.94 |
Enterprise Value | $38.15B | $40.68B |
Dividend Yield | — | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Dollar General (DG) trades at $118.92, up 2.76% today, with a neutral technical signal and bearish moving averages. The stock shows strong valuation metrics with a P/E of 16.82 and P/S of 0.61, supported by three consecutive quarterly earnings beats. Revenue grew to $40.61B in 2025, though net margins compressed to 2.77%. Positive news highlights margin expansion and back-to-school initiatives, while cash flow improved to $395M net.
Outlook remains cautiously optimistic with a $128.45 consensus price target implying 8% upside. Risks include margin pressure from inflation and competitive threats. Analyst consensus is 52% Buy, but weak consumer sentiment and technical resistance near $120 may limit near-term gains. Debt reduction trends and dividend coverage provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
